TY - JOUR
T1 - Inadequate detection of the FSHR complicates future research on extragonadal FSHR localization
AU - Tedjawirja, Victoria N.
AU - Hooijer, Gerrit K. J.
AU - Savci-Heijink, C. Dilara
AU - Kovac, Kristina
AU - Balm, Ron
AU - de Waard, Vivian
N1 - Funding Information:
This work is financed by the Ministry of Economic Affairs by means of the Private-Public-Partnership Allowance made available by the Top Sector Life Sciences & Health to stimulate public-private Partnerships and by funding of Amsterdam UMC (project NR4Ants). The study was supported by the AMC Foundation.
Publisher Copyright:
Copyright © 2023 Tedjawirja, Hooijer, Savci-Heijink, Kovac, Balm and de Waard.
PY - 2023
Y1 - 2023
N2 - Introduction: Recently, follicle stimulating hormone (FSH) through interaction with its receptor (FSHR) has been proposed to play a role in postmenopausal osteoporosis and cardiovascular disease, rather than the loss of estrogen. To explore this hypothesis, unravelling which cells express extragonadal FSHR on protein level is key. Methods: We used two commercial anti-FSHR antibodies and validated them by performing immunohistochemistry on positive (ovary, testis) and negative controls (skin). Results: The monoclonal anti-FSHR antibody could not identify the FSHR in ovary or testis. The polyclonal anti-FSHR antibody stained the granulosa cells (ovary) and Sertoli cells (testis), yet there was equally intense staining of other cells/extracellular matrix. Furthermore, the polyclonal anti-FSHR antibody also stained skin tissue extensively, suggesting that the antibody stains more than just FSHR. Discussion: The findings in this study may add accuracy to literature on extragonadal FSHR localization and warrants attention to the use of inadequate anti-FSHR antibodies to value the potential role of FSH/FSHR in postmenopausal disease.
AB - Introduction: Recently, follicle stimulating hormone (FSH) through interaction with its receptor (FSHR) has been proposed to play a role in postmenopausal osteoporosis and cardiovascular disease, rather than the loss of estrogen. To explore this hypothesis, unravelling which cells express extragonadal FSHR on protein level is key. Methods: We used two commercial anti-FSHR antibodies and validated them by performing immunohistochemistry on positive (ovary, testis) and negative controls (skin). Results: The monoclonal anti-FSHR antibody could not identify the FSHR in ovary or testis. The polyclonal anti-FSHR antibody stained the granulosa cells (ovary) and Sertoli cells (testis), yet there was equally intense staining of other cells/extracellular matrix. Furthermore, the polyclonal anti-FSHR antibody also stained skin tissue extensively, suggesting that the antibody stains more than just FSHR. Discussion: The findings in this study may add accuracy to literature on extragonadal FSHR localization and warrants attention to the use of inadequate anti-FSHR antibodies to value the potential role of FSH/FSHR in postmenopausal disease.
KW - antibodies
KW - control
KW - extragonadal cells
KW - follicle stimulating hormone receptor
KW - immunohistochemistry
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85149522730&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/36875462
U2 - 10.3389/fendo.2023.1095031
DO - 10.3389/fendo.2023.1095031
M3 - Article
C2 - 36875462
SN - 1664-2392
VL - 14
JO - Frontiers in Endocrinology
JF - Frontiers in Endocrinology
M1 - 1095031
ER -